KR101106963B1 - P1 유전자를 이용한 마이코플라스마 뉴모니아균 검출용 pcr 프라이머와 프로브 및 이를 이용한 실시간 pcr 방법 - Google Patents
P1 유전자를 이용한 마이코플라스마 뉴모니아균 검출용 pcr 프라이머와 프로브 및 이를 이용한 실시간 pcr 방법 Download PDFInfo
- Publication number
- KR101106963B1 KR101106963B1 KR1020090081654A KR20090081654A KR101106963B1 KR 101106963 B1 KR101106963 B1 KR 101106963B1 KR 1020090081654 A KR1020090081654 A KR 1020090081654A KR 20090081654 A KR20090081654 A KR 20090081654A KR 101106963 B1 KR101106963 B1 KR 101106963B1
- Authority
- KR
- South Korea
- Prior art keywords
- mycoplasma pneumoniae
- oligonucleotide
- pcr
- probe
- detecting
- Prior art date
Links
- 239000000523 sample Substances 0.000 title claims abstract description 69
- 241000202934 Mycoplasma pneumoniae Species 0.000 title claims abstract description 67
- 238000003753 real-time PCR Methods 0.000 title claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims description 64
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 41
- 238000001514 detection method Methods 0.000 claims abstract description 22
- 230000000241 respiratory effect Effects 0.000 claims abstract description 19
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 11
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 11
- 230000000295 complement effect Effects 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims description 8
- 241000204003 Mycoplasmatales Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000036425 denaturation Effects 0.000 claims description 6
- 238000004925 denaturation Methods 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 claims description 5
- 238000005202 decontamination Methods 0.000 claims description 3
- 230000003588 decontaminative effect Effects 0.000 claims description 3
- 241001072332 Monia Species 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 17
- 239000013610 patient sample Substances 0.000 abstract description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 10
- 239000007850 fluorescent dye Substances 0.000 description 9
- 238000001215 fluorescent labelling Methods 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 7
- 206010057190 Respiratory tract infections Diseases 0.000 description 6
- 241000194017 Streptococcus Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- 241000202966 Mycoplasma lipophilum Species 0.000 description 1
- 241000462791 Mycoplasma pneumoniae FH Species 0.000 description 1
- 241000432072 Mycoplasma pneumoniae M129 Species 0.000 description 1
- 241000202889 Mycoplasma salivarium Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194025 Streptococcus oralis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229940115922 streptococcus uberis Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Name | Sequence (5' → 3') | Product size |
DD50B | 5'-gca aag tta tgg aaa cat aat gga ggt t(서열번호 1) | 427bp |
DD54B | 5'-ggt tag caa cac gtt ttt aaa tat t (서열번호 2) |
성 분 | 부피 |
DNA template (검체 DNA) | 5㎕ |
10 x reaction buffer (2.5mM MgCl2 포함) | 5㎕ |
dNTP mixture (each 10mM) | 1㎕ |
DD50B (20pmol/㎕) | 1㎕ |
DD54B (20pmol㎕) | 1㎕ |
Taq DNA polymerase (0.5U) | 0.5㎕ |
Band doctor | 1㎕ |
멸균 증류수 | 35.5㎕ |
총 부 피 | 50㎕ |
반응온도 | 시간 | 반복주기 |
94℃ | 4분 | 1회 |
94℃ | 30초 | 30회 |
62℃ | 30초 | |
72℃ | 1분 | |
72℃ | 10분 | 1회 |
Name | Sequence (5' → 3') |
repMP1b-F | AACGAAAAAGAATTCCATGACATG(서열번호 3) |
repMP1b-R | AATTCCACACTGTTGTTCTCTG(서열번호 4) |
Probe | FAM 5'-ACGATGTATCAACCTGAAAAAGTGCCCT-3' TAMRA(서열번호 5) |
Components | Volume (㎕) |
TaqMan universal PCR master mix | 10 |
Primer repMP1b-F (10pmol/㎕) | 1 |
Primer repMP1b-R (10pmol/㎕) | 1 |
Probe (2.5pmol/㎕) | 1 |
검체 DNA | 2 |
멸균 증류수 | 5 |
Total volume (㎕) | 20 |
Stage | Temperature | Duration time | Cycles |
Decontamination | 50℃ | 2 min | 1 |
Initial denaturation | 95℃ | 10 min | 1 |
Denaturation | 95℃ | 15 sec | 40 |
Extension | 60℃ | 1 min |
Groups | Bacteria |
Other Mycoplasma spp. | |
Mycoplasma salivarium | |
Mycoplasma orale | |
Mycoplasma bovis | |
Mycoplasma fermentants | |
Mycoplasma hominis | |
Mycoplasma lipophilum | |
Atypical pathogens of community-acquired pneumonia | |
Chlamydia pneumoniae | |
Chlamydia psittaci | |
Legionella pnemophilla | |
Causative bacteria of community-acquired pneumonia | |
Streptococcus pneumoniae | |
Haemophilus influenzae | |
Staphylococcus aureus | |
Moraxella catarrhalis | |
Pseudomonas aeruginosa | |
Other respiratory pathogens | |
Streptococcus pyogens | |
Neisseria meningitidis | |
Bordetella pertusis | |
Oral commensal bacteria and other bacteria | |
Streptococcus agalactiae | |
Streptococcus bovis | |
Streptococcus cremolis | |
Streptococcus dysagalactiae | |
Streptococcus epidermis | |
Streptococcus euqi | |
Streptococcus lactis | |
Streptococcus mitis | |
Streptococcus mutans | |
Streptococcus oralis | |
Streptococcus sanguis | |
Streptococcus uberis | |
Acinetobacter baumannii | |
Escherichia coli | |
Enterococcus faecalis |
CCU/㎖ | 1010 | 109 | 108 | 107 | 106 | 105 | 104 | 103 | 102 | 101 | 100 | 10-1 |
Ct value | 19.8 | 22.8 | 25.5 | 29.3 | 32.4 | 34.9 | 36.9 | 37.5 | 38.8 | 39.1 | 39.9 | - |
Results | No. of cases (%) | |
Real-time PCR | Conventional PCR | |
Positive | 43 (27.9%) | 36 (23.4%) |
Negative | 111 (72.1%) | 118 (76.6%) |
Total | 154 (100.0%) |
Claims (9)
- 서열번호 3의 올리고뉴클레오티드 및 서열번호 4의 올리고뉴클레오티드를 포함하는 마이코플라스마 뉴모니아균에 특이적인 표적 서열을 증폭할 수 있는 P1 유전자를 이용한 마이코플라스마 뉴모니아균 검출용 PCR 프라이머 세트.
- 서열번호 5의 올리고뉴클레오티드 및 그에 상보적인 올리고뉴클레오티드에서 선택되는 하나 이상의 마이코플라스마 뉴모니아로부터 유래한 핵산에 특이적인 올리고뉴클레오티드 검출용 프로브.
- 호흡기 검체로부터 분리된 핵산을 주형으로 하여 제1항에 따른 프라이머 세트를 이용하여 PCR을 수행하는 단계; 및얻어진 PCR 산물을 사용하여 검체 중의 표적 서열을 검출하는 단계를 포함하는 마이코플라스마 뉴모니아균을 검출하는 실시간 PCR 방법.
- 제3항에 있어서, 상기 표적 서열을 검출하는 단계는 제2항에 따른 프로브를 사용하여 검체 중의 표적 서열을 검출하는 것을 특징으로 하는 마이코플라스마 뉴모니아균을 검출하는 실시간 PCR 방법.
- 제4항에 있어서, 상기 프로브의 3' 말단 또는 5' 말단이 FAM, VIC, TAMRA, JOE, ROX, NED, HEX 및 TET로 이루어진 군으로부터 선택되는 형광인자로 표지되는 것을 특징으로 하는 마이코플라스마 뉴모니아균을 검출하는 실시간 PCR 방법.
- 제5항에 있어서, 상기 PCR 방법은 PCR 마스터 혼합물(master mix) 10㎕, 프라이머 repMP1b-F (10pmol/㎕) 1㎕, 프라이머 repMP1b-R (10pmol/㎕) 1㎕, 프로브 (2.5pmol/㎕) 1㎕, 검체 DNA 2㎕, 멸균 증류수 5㎕를 포함하여 총 부피가 20 ㎕가가 되는 것을 특징으로 하는 마이코플라스마 뉴모니아균 검출하는 실시간 PCR 방법.
- 제6항에 있어서, 상기 PCR 방법은 정화(Decontamination) 50℃ 2분 1회, 초기변성(Initial denaturation) 95℃ 10분 1회, 변성(Denaturation) 95℃ 15초 40회, 연장(Extension) 60℃ 1분 40회를 실시하는 것을 특징으로 하는 마이코플라스마 뉴모니아균 검출하는 실시간 PCR 방법.
- 서열번호 3의 올리고뉴클레오티드 및 서열번호 4의 올리고뉴클레오티드를 포함하는 마이코플라스마 뉴모니아균에 특이적인 표적 서열을 증폭할 수 있는 P1 유전자를 이용한 마이코플라스마 뉴모니아균 검출용 PCR 프라이머 세트; 및서열번호 5의 올리고뉴클레오티드 및 그에 상보적인 올리고뉴클레오티드에서 선택되는 하나 이상의 마이코플라스마 뉴모니아로부터 유래한 핵산에 특이적인 올 리고뉴클레오티드 검출용 프로브를 포함하는 마이코플라스마 뉴모니아균 검출용 키트.
- 제8항에 있어서, 상기 프로브의 3' 말단 또는 5'말단이 FAM, VIC, TAMRA, JOE, ROX, NED, HEX 및 TET로 이루어진 군으로부터 선택되는 형광인자로 표지되는 것을 특징으로 하는 마이코플라스마 뉴모니아균 검출용 키트.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090081654A KR101106963B1 (ko) | 2009-08-31 | 2009-08-31 | P1 유전자를 이용한 마이코플라스마 뉴모니아균 검출용 pcr 프라이머와 프로브 및 이를 이용한 실시간 pcr 방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090081654A KR101106963B1 (ko) | 2009-08-31 | 2009-08-31 | P1 유전자를 이용한 마이코플라스마 뉴모니아균 검출용 pcr 프라이머와 프로브 및 이를 이용한 실시간 pcr 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110023641A KR20110023641A (ko) | 2011-03-08 |
KR101106963B1 true KR101106963B1 (ko) | 2012-01-20 |
Family
ID=43931733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090081654A KR101106963B1 (ko) | 2009-08-31 | 2009-08-31 | P1 유전자를 이용한 마이코플라스마 뉴모니아균 검출용 pcr 프라이머와 프로브 및 이를 이용한 실시간 pcr 방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101106963B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240147866A (ko) | 2023-03-31 | 2024-10-10 | 주식회사 비피도 | 검체 내 비피도박테리움 롱검 rapo 균주 검출방법 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110804669B (zh) * | 2019-11-28 | 2022-12-16 | 广州微远医疗器械有限公司 | 用于肺炎支原体的crispr检测引物组及其用途 |
-
2009
- 2009-08-31 KR KR1020090081654A patent/KR101106963B1/ko active IP Right Grant
Non-Patent Citations (3)
Title |
---|
Infection and Immunity, Vol. 67, No. 9, pp.4557-4562 (1999) |
Infection and Immunity, Vol. 69, No. 9, pp.5612-5618 (2001) |
Infection and Immunity, Vol. 76, No. 4, pp.1639-1648 (2008) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240147866A (ko) | 2023-03-31 | 2024-10-10 | 주식회사 비피도 | 검체 내 비피도박테리움 롱검 rapo 균주 검출방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20110023641A (ko) | 2011-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4176146B2 (ja) | 微生物検査室における日常的診断用の臨床検体からの通常の細菌病原体および抗生物質耐性遺伝子を迅速に検出および同定するための特異的および普遍的プローブおよび増幅プライマー | |
KR101038519B1 (ko) | 인체 감염성질환 병원체 감별진단 및 이의 항생제 내성 유무 판별방법, 멀티플렉스 키트 그리고 이를 포함하는 칩 | |
EP2547782B1 (en) | Methods, kits and compositions for detection of mrsa | |
JP2010524454A (ja) | 抗生物質耐性細菌の検出および分析のための方法、組成物、およびキット | |
CN102533959A (zh) | 一种鉴别结核分枝杆菌的多重pcr试剂盒 | |
US20130065232A1 (en) | Assays and kits for serotyping pseudomonas aeruginosa and oligonucleotide sequences useful in such methods and kits | |
WO2014008312A2 (en) | Primers, assays and methods for detecting an e. coli subtype | |
Book et al. | Monitoring infection: from blood culture to polymerase chain reaction (PCR) | |
WO2015103710A1 (en) | Methods, reagents and kits for the assessment of bacterial infection | |
CN110643722A (zh) | 一种淋病奈瑟菌耐药位点多重检测方法及试剂盒 | |
US20180230520A1 (en) | Primers for the detection and typing of carbapenemase-producing bacterial strains and detection method and kit | |
EP2279269B1 (en) | Rapid detection of mycobacteria | |
KR101106963B1 (ko) | P1 유전자를 이용한 마이코플라스마 뉴모니아균 검출용 pcr 프라이머와 프로브 및 이를 이용한 실시간 pcr 방법 | |
KR20130097974A (ko) | 황색포도상구균의 분자적 동정을 위한 프라이머 및 이를 이용한 황색포도상구균 동정 방법 | |
Couzinet et al. | High-density DNA probe arrays for identification of staphylococci to the species level | |
JP2006271370A (ja) | 黄色ブドウ球菌とメチシリン耐性菌の検出方法及びキット | |
CN107937579A (zh) | 一种用于检测血培养瓶中临床常见病原菌的产品和方法 | |
EP0739987A2 (en) | Oligonucleotides for detecting Salmonella species and detection process using the same | |
CN107236793A (zh) | 一种棒状杆菌属细菌和克氏棒状杆菌多重荧光定量pcr引物、探针、试剂盒和检测方法 | |
EP3438280B1 (en) | Haemoplasma detection method | |
KR101765677B1 (ko) | 결핵 및 비결핵 항산균 검출용 프라이머 세트 및 이를 이용한 검출 방법 | |
Shah et al. | Infection of Mycobacterium mageritense at surgical site: A first case report of India. | |
TW202204635A (zh) | 銀色葡萄球菌之檢測用之引子組及探針 | |
CN110129463A (zh) | 一种用于头状葡萄球菌检测的试剂盒 | |
EP2723891B1 (en) | Diagnostic methods for detecting clostridium difficile |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20090831 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110602 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20111223 |
|
GRNT | Written decision to grant | ||
PR0702 | Registration of establishment of national patent |
Patent event code: PR07021E01D Comment text: Registration of Establishment of National Patent Patent event date: 20120111 |
|
PR1002 | Payment of registration fee |
Payment date: 20120111 End annual number: 20 Start annual number: 1 |
|
PG1601 | Publication of registration |